Omnicell (NASDAQ:OMCL) Updates Q2 2026 Earnings Guidance

Key Points

• Guidance update: Omnicell issued Q2 2026 guidance of EPS "0.400-48.000" and revenue of $307.0M–$313.0M, and set FY 2026 EPS guidance at 1.800–2.000, versus Q2 consensus estimates of $0.37 EPS and $304.3M revenue.
• Quarterly beat: The company reported Q2 results of $0.55 EPS (vs. $0.33 consensus) and $309.88M in revenue (vs. $304.01M consensus), outperforming analyst estimates.
• Analyst and stock backdrop: Analysts hold a "Moderate Buy" consensus with an average target of $59.00, while shares trade near $37.63 with a one‑year range of $22.66–$55.00.

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.400-48.000 for the period, compared to the consensus EPS estimate of 0.370. The company issued revenue guidance of $307.0 million-$313.0 million, compared to the consensus revenue estimate of $304.3 million. Omnicell also updated its FY 2026 guidance to 1.800-2.000 EPS.

Analyst Ratings Changes

OMCL has been the topic of a number of recent analyst reports. UBS Group set a $60.00 price objective on Omnicell and gave the stock a "buy" rating in a research note on Friday, March 13th. KeyCorp raised shares of Omnicell from a "sector weight" rating to an "overweight" rating and set a $60.00 target price for the company in a research report on Wednesday, January 7th. Zacks Research upgraded shares of Omnicell from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. Finally, Wells Fargo & Company increased their price objective on shares of Omnicell from $52.00 to $55.00 and gave the stock an "overweight" rating in a research report on Thursday, April 23rd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $59.00.

Omnicell Stock Up 0.7%

Shares of Omnicell stock opened at $37.63 on Tuesday. The stock's 50-day moving average is $36.86 and its 200 day moving average is $39.29. Omnicell has a one year low of $22.66 and a one year high of $55.00. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 940.99, a PEG ratio of 1.34 and a beta of 0.85. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. The firm had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.01 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Equities research analysts anticipate that Omnicell will post 0.92 EPS for the current year.

Insider Transactions at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of the business's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.52% of the company's stock.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in shares of Omnicell in the second quarter valued at $26,000. Kemnay Advisory Services Inc. bought a new stake in shares of Omnicell during the fourth quarter worth about $58,000. Parkside Financial Bank & Trust raised its holdings in shares of Omnicell by 1,708.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. Van ECK Associates Corp lifted its position in Omnicell by 75.1% in the 4th quarter. Van ECK Associates Corp now owns 2,294 shares of the company's stock valued at $104,000 after acquiring an additional 984 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock valued at $146,000 after purchasing an additional 3,932 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.